Balance Sheet HealthLow reported leverage and a sizable equity base provide durable financial flexibility for a clinical-stage biotech. This reduces near-term bankruptcy risk, supports continued R&D spending or licencing deals, and gives management time to advance programs or raise capital under less distressed conditions.

Improving Cash BurnA reduction in cash burn versus the prior year signals improving operational discipline or milestone-driven spend timing. Sustained lower burn extends runway, lessens financing frequency, and increases the chance that upcoming clinical or partner events can be achieved without immediate dilutive financing.

Narrowing LossesNarrowing operating and net losses over time suggest progress toward cost control or efficiency gains in R&D/operations. If sustained, this trend improves prospects of reaching break-even after commercialization or partnerships and increases appeal to investors and partners focused on cash efficiency.

Bears Say

Zero Recent RevenueThe absence of recent revenue is a structural weakness: without product sales the company cannot self-fund development long-term. This increases dependency on external financing or licensing, heightens dilution risk, and makes progress contingent on successful clinical or partner milestones rather than organic cash generation.

Consistent Negative Cash FlowPersistent negative operating and free cash flow show ongoing funding needs and limited internal cash generation. Over months, this forces recurring capital raises or asset sales, constrains strategic choices, and elevates execution risk if capital markets or partner options are unavailable when needed.

Eroding Equity BaseA declining equity and asset base over successive years signals that losses are eroding financial cushions. This reduces borrowing capacity, limits ability to absorb setbacks, and makes future fundraising more dilutive or difficult, raising the structural risk to continued R&D investment and program advancement.

IMMU FAQ

What was Immunicum AB’s price range in the past 12 months?

Immunicum AB lowest stock price was kr3.90 and its highest was kr10.98 in the past 12 months.

What is Immunicum AB’s market cap?

Immunicum AB’s market cap is kr254.73M.

When is Immunicum AB’s upcoming earnings report date?

Immunicum AB’s upcoming earnings report date is May 08, 2026 which is in 55 days.

How were Immunicum AB’s earnings last quarter?

Immunicum AB released its earnings results on Feb 11, 2026. The company reported -kr0.74 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.74.

Is Immunicum AB overvalued?

According to Wall Street analysts Immunicum AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Immunicum AB pay dividends?

Immunicum AB does not currently pay dividends.

What is Immunicum AB’s EPS estimate?

Immunicum AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Immunicum AB have?

Immunicum AB has 62,584,580 shares outstanding.

What happened to Immunicum AB’s price movement after its last earnings report?

Immunicum AB reported an EPS of -kr0.74 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.055%.

Which hedge fund is a major shareholder of Immunicum AB?

Currently, no hedge funds are holding shares in SE:IMMU

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Immunicum AB

Mendus AB (publ), a biopharmaceutical company, develops immunotherapies and relapse vaccines for the treatment of cancer. Its lead product is ilixadencel, which is in Phase II MERECA clinical trial for the treatment of kidney cancer; and Phase I/II clinical trial to treat liver cancer and gastrointestinal stromal tumors. The company's products also comprise DCP-001, which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia; and Phase I/II ALISON clinical trial for the treatment of ovarian cancers. It has a research collaboration with PCI Biotech Holding ASA for novel cancer vaccination treatment; and with Icahn School of Medicine at Mount Sinai. The company was formerly known as Immunicum AB (publ) and changed its name to Mendus AB (publ) in June 2022. Mendus AB (publ) was incorporated in 2002 and is headquartered in Stockholm, Sweden.